Treatment landscape and survival outcomes among patients treated for Mantle Cell Lymphoma in real-world practice

ASH 2026 • MCL • Zanubrutinib • Poster

Krish Patel, MD

DISCLAIMER

The contents of the presentation are designed for educational and scientific exchange purposes and are not promotional. They may contain information on investigational products or investigational uses of approved products. No conclusions regarding safety and/or efficacy for such investigational products or uses may be made.

SUMMARY

This retrospective study assessed real-world treatment patterns across multiple lines of therapy and assessed clinical outcomes in patients with mantle cell lymphoma, using the Flatiron Health database. A total of 4,674 patients who initiated first-line therapy between 2016 and 2025 were included. Among those tested, TP53 mutations were present in 25% (n=222/906) and Ki67 ≥30% in 48% (n=1513/3171). Overall, 11% of patients received aggressive (cytarabine-containing) first-line therapy and 67% received less-aggressive first-line therapy. Bendamustine-rituximab remained the most common frontline therapy (45% of all first-line regimens), while covalent Bruton tyrosine kinase inhibitor (cBTKi) use increased across treatment lines (31% in second-line, 20% in third-line, and 13% in fourth-line). Median real-world time to next treatment from first-line therapy was 20 months (95% CI, 19-22) and median real-world overall survival (OS) was 71 months (95% CI, 67-75). Patients receiving aggressive frontline therapy had longer median OS than those receiving less-intensive regimens: 112 months (95% CI, 107-not reached) vs 68 months (95% CI, 64-74), respectively. Among 839 patients receiving therapy after cBTKi exposure, common approaches included additional cBTKi-containing regimens (36%), chemoimmunotherapy (15%), pirtobrutinib-containing regimens (11%), and CAR T-cell therapy (8%). In this post-cBTKi subgroup, median real-world time to next treatment was 6 months (95% CI, 6-7) and median OS was 27 months (95% CI, 23-31).

You are now leaving the website

This link is provided for information purposes only. You’ll be leaving beonemedaffairs.com and accessing a third-party website over which [BeOne Medicines | GmbH] has no control or influence.

This link will take you to a third-party website outside of beonemedaffairs.com.

[BeOne Medicines | GmbH] has no control over this website and makes no representations regarding its content or availability in your location. [BeOne Medicines | GmbH] declines any responsibility for third-party information, data usage policies, or personal data processing.

By proceeding, you acknowledge that you are part of the intended audience of the third-party website and confirm your compliance with applicable laws.

Do you want to leave beonemedaffairs.com

You are now leaving the website beonemedaffairs.com and entering another BeOne website with different terms of use. Information included on this website may not be specific to your country. Click Continue to proceed